Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis
ConclusionILD was observed in 18.9% of PDAC patients treated with GnP therapy. With appropriate management, no prognostic influence was observed.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Interstitial Lung Disease | Pancreas | Pancreatic Cancer | Steroid Therapy